ライフサイエンスコーパス: ventricular enlargement

1 on external CT scans and scans demonstrating ventricular enlargement.

2 for treating excessive CSF accumulation and ventricular enlargement.

3 , along with moderate widespread atrophy and ventricular enlargement.

4 ovide insight into a mechanism of reversible ventricular enlargement.

5 hemorrhage or (2) parenchymal lesions and/or ventricular enlargement.

6 t with cortical thinning/sulcal widening and ventricular enlargement.

7 greater severity, especially with regard to ventricular enlargement.

8 y could be shown in those who developed left ventricular enlargement.

9 Patients did not demonstrate evidence of ventricular enlargement.

10 ts and correlate with olfactory deficits and ventricular enlargement.

11 ation deficits and age-dependent progressive ventricular enlargements.

12 ge loss 0.17% (CI 0.07 to 0.27) and absolute ventricular enlargement 1.78% (CI 1.14 to 2.92) higher i

13 matter volume deficits (-0.7 SD) and fourth ventricular enlargement (1.6 SD); these abnormalities we

14 , hippocampal atrophy (30 mm3 per year), and ventricular enlargement (565 mm3 per year).

15 scans were calcifications (99%), followed by ventricular enlargement (94%), cortical hypogyration (81

16 Ventricular enlargement, a common in vivo marker of agin

17 Progressive ventricular enlargement, a key feature of several neurol

18 ft ventricular systolic dysfunction and left ventricular enlargement after excluding usual clinical c

19 ft ventricular systolic dysfunction and left ventricular enlargement after excluding usual clinical c

20 umferential function might serve to restrain ventricular enlargement after MI.

21 s with reduced left ventricular function and ventricular enlargement after myocardial infarction are

22 gy utilization is associated with subsequent ventricular enlargement, an indirect measure of central

23 n age-independent analyses, show significant ventricular enlargement and also suggest progression of

24 covery rate, k(PCr)) is associated with less ventricular enlargement and brain aging progression, and

25 Lateral ventricular enlargement and brain volume reductions of a

26 fibrosis, and lipid accumulation, along with ventricular enlargement and cardiac dysfunction in both

27 aracterizing structural progression, such as ventricular enlargement and cardiac dysfunction, in ARVD

28 ed and confirmed by meta-analysis, including ventricular enlargement and decreased cerebral (cortical

29 nd abnormalities in brain morphology such as ventricular enlargement and differences in gray matter d

30 Worse RA LS was also associated with right ventricular enlargement and dysfunction and higher N-ter

31 tethering-factors often influenced by right ventricular enlargement and dysfunction.

32 e decrease in pathological CSF accumulation, ventricular enlargement and other associated disease sym

33 ficantly less brain atrophy as quantified by ventricular enlargement and preserved cortical volume in

34 revious findings in Wistar rats and included ventricular enlargement and reduced MRS-derived creatine

35 cardiac disease characterized by progressive ventricular enlargement and reduced systolic function.

36 eks, the phenotype progressed to marked left ventricular enlargement and severely depressed systolic

37 in cognitive functioning and have detectable ventricular enlargement and some loss of cortical mass.

38 onal magnetic resonance microscopy indicated ventricular enlargement and striatal reduction in both m

39 ion; dilated cardiomyopathy (DCM), with left ventricular enlargement and systolic dysfunction; and ar

40 Diabetes modified the relationship between ventricular enlargement and the risk of HF (P=0.011).

41 ship between cortical gray matter deficit or ventricular enlargements and age at symptom onset or len

42 sociated with pulmonary regurgitation, right ventricular enlargement, and a substrate of discrete, sl

43 itulates the primary periventricular lesion, ventricular enlargement, and the secondary cortical defi

44 ules and pathomechanisms underlying cerebral ventricular enlargement are widely unknown.

45 Hypoxia also correlated significantly with ventricular enlargement, but only among patients (effect

46 ble and progressive process characterized by ventricular enlargement, chamber geometric alterations,

47 ased lung uptake chi2=9.6, P=0.002; and left ventricular enlargement chi2=8.3, P=0.004.

48 Ventricular enlargement due to right ventricular volume

49 t ventricular disease, as estimated by right ventricular enlargement during detailed echocardiography

50 d flow, leading to olfactory dysfunction and ventricular enlargement, early neuropathological feature

51 cause previous data showed progressive brain ventricular enlargement for a group of adolescents with

52 Pathological mechanisms underlying ventricular enlargement, however, are likely specific to

53 Progressive left ventricular enlargement, hypocontractility, left atrial

54 ration of ciliary motility and age-dependent ventricular enlargement in 22q11DS.

55 The rate of ventricular enlargement in alcoholic patients who mainta

56 s were abnormal in 3 of 10 patients, showing ventricular enlargement in one, periventricular hyperint

57 combined treatment significantly attenuated ventricular enlargement in vivo.

58 romotes cardiomyocyte migration in vitro and ventricular enlargement in vivo.

59 nd reduced activity, cardiac dysfunction and ventricular enlargement in zebrafish.

60 celerated cortical thinning but noted faster ventricular enlargements in BD.

61 Parenchymal lesions/ventricular enlargement increased risk for current atten

62 he entire sample, parenchymal lesions and/or ventricular enlargement increased risk relative to no ab

63 of normal intelligence, parenchymal lesions/ventricular enlargement independently increased risk for

64 Ventricular enlargement is unique to the clinical phenot

65 HF rabbits had left ventricular enlargement (left ventricular end-diastolic

66 Less iron deposition and ventricular enlargement, lower brain water content, and

67 FDRs, or for DCM partial phenotypes of left ventricular enlargement (LVE) or left ventricular systol

68 Twenty percent (n = 45) had left ventricular enlargement (LVE), defined as LV end-diastol

69 symptomatic family members was based on left ventricular enlargement (LVE).

70 lsequestrin mice at 7 weeks showed mild left ventricular enlargement, mild decreased fractional short

71 structural alterations, including atrial and ventricular enlargement, myofibril disarray, fibrosis an

72 By contrast, fourth ventricular enlargement occurred in schizophrenia even w

73 Nonetheless, striatal shrinkage and ventricular enlargement occurred, and striatal projectio

74 We investigated the prognostic role of right ventricular enlargement on multidetector-row chest CT in

75 Right ventricular enlargement on the reconstructed CT 4-CH vie

76 ho underwent rescreening, two (one with left ventricular enlargement only, one with a left bundle bra

77 scar is rare, an important minority exhibits ventricular enlargement or dysfunction.

78 efined by the presence of DCM or either left ventricular enlargement or left ventricular systolic dys

79 For example, ventricular enlargement or reduced caudate volume or blo

80 tients with poor outcome had greater lateral ventricular enlargement over time than patients with goo

81 Relationships between ventricular enlargements potentially contributing to cal

82 zed Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) study was designed to

83 zed Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial after a screeni

84 lirium was strongly associated with age, and ventricular enlargement, primarily in the lateral ventri

85 nd between increase in MSFC and both rate of ventricular enlargement (r=0.31, P<0.05) and increase in

86 Lateral ventricular enlargement represents a potential morphomet

87 represented by changes in ADAS13 scores and ventricular enlargement, respectively.

88 We used data from the Survival and Ventricular Enlargement (SAVE) echocardiographic substud

89 ion [LVEF] < or = 40%) from the Survival And Ventricular Enlargement (SAVE) echocardiographic substud

90 thmias in 263 patients from the Survival and Ventricular Enlargement (SAVE) study, using quantitative

91 The Survival And Ventricular Enlargement (SAVE) trial randomized 2231 pat

92 nction and were enrolled in the Survival and Ventricular Enlargement (SAVE) trial were studied.

93 despread deficit in cortical gray matter and ventricular enlargement similar to that seen in men with

94 n cortical gray and white matter volumes and ventricular enlargement similar to those seen in alcohol

95 e study cohort consisted of 727 Survival and Ventricular Enlargement Study patients who underwent car

96 d that continuous decorin infusion prevented ventricular enlargement, such that ventricle size remain

97 recursors) or (2) parenchymal lesions and/or ventricular enlargement (suggestive of white matter inju

98 en, women had surgery rarely for severe left ventricular enlargement (systolic diameter > or = 55 mm

99 rction who were enrolled in the Survival and Ventricular Enlargement trial.

100 ust to anatomical variability, including the ventricular enlargement typically associated with neurol

101 nt in ejection fraction, but persistent left ventricular enlargement was more frequent in group 1.

102 More consistent progressive ventricular enlargement was seen during adolescence for

103 ant cortical gray matter deficit and lateral ventricular enlargement were found in schizophrenic pati

104 d left- and right-sided pressures, and right ventricular enlargement were independently predictive of

105 Parenchymal lesions/ventricular enlargement were not related to lifetime att

106 ads to a hypercompliant cortex and secondary ventricular enlargement without primary defects in CSF c